Literature DB >> 114648

The aurosome.

F N Ghadially.   

Abstract

Aurosomes are lysosomal bodies containing gold. Colloidal gold produces aurosomes containing spherical electron-dense granules. Soluble gold salts produce aurosomes containing lamellar, filamentous and rod-like profiles studded with particles and granules. This morphological pattern is quite distinctive, and is not affected or altered by which particular soluble gold salt is administered, by which route it is administered or in which species or cell type the aurosome occurs. In the skin of patients treated with soluble gold salts the characteristics electron-dense formations indicating the presence of gold are often found in compound melanosomes and other lysosomes in the dermal macrophages; while in the synovial membrane these characteristic electron-dense deposits are seen in the numerous lysosomes that develop in the rheumatoid synovial membrane. Thus it would appear that while aurosomes may vary somewhat in morphology, the electron dense contents indicating the presence of gold have a fairly constant morphology.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 114648

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  9 in total

1.  Systems approach to metal-based pharmacology.

Authors:  Isolda Romero-Canelón; Peter J Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

Review 2.  Clinical pharmacokinetics of oral and injectable gold compounds.

Authors:  K L Blocka; H E Paulus; D E Furst
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 3.  Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Observations on extravascular pharmacokinetics.

Authors:  W J Wallis; P A Simkin
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

Review 4.  Gold-based therapy: From past to present.

Authors:  Alice Balfourier; Jelena Kolosnjaj-Tabi; Nathalie Luciani; Florent Carn; Florence Gazeau
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-08       Impact factor: 11.205

Review 5.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

6.  Crystalline and amorphous gold in chrysiasis.

Authors:  H P Benn; B von Gaudecker; M Czank; H Loeffler
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

7.  Gold levels produced by treatment with auranofin and sodium aurothiomalate.

Authors:  D Lewis; H A Capell; C J McNeil; M S Iqbal; D H Brown; W E Smith
Journal:  Ann Rheum Dis       Date:  1983-10       Impact factor: 19.103

8.  Phagocytes render chemicals immunogenic: oxidation of gold(I) to the T cell-sensitizing gold(III) metabolite generated by mononuclear phagocytes.

Authors:  C Goebel; M Kubicka-Muranyi; T Tonn; J Gonzalez; E Gleichmann
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

Review 9.  Prospecting Cellular Gold Nanoparticle Biomineralization as a Viable Alternative to Prefabricated Gold Nanoparticles.

Authors:  Aaron S Schwartz-Duval; Konstantin V Sokolov
Journal:  Adv Sci (Weinh)       Date:  2022-05-04       Impact factor: 17.521

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.